Elderly travel up to 44km to get hospitalised: Lancet
Researchers analysed data of nearly 32,000 older adults, aged 60 and above, collected during the first wave of the
Longitudinal Ageing Study of India
(LASI) in 2017-2018 and found there was a significant urban-rural disparity also with the urban older adults availing out-patient facilities within 10 km of reach, while the distance was nearly 30 km for their rural counterparts.
According to the Lancet study, rates of availing both out-patient and in-patient services were found to be high - 73% and 40%, respectively - when a facility was within 10 km of reach. However, with an increase in commute distance, a commensurate decline in the use of out-patient services was found - 17% utilisation of facilities for 11-30 km distance, and 10% for 30 km and above, respectively, it adds.
A longer commute and far-away facility is a barrier for receiving timely, essential healthcare for people in this age group, often seen grappling with multiple long-term, debilitating conditions requiring continuous care, the research team said. They wrote, "Older adults, on an average, travelled a distance of nine miles (14.5 kilometres) to seek outpatient services and 27 miles (43.6 kilometres) for inpatient care respectively."
State-wise, Tripura, Manipur and Kerala, had the highest in-patient and outpatient visits within 10 km - over 80%, 75% and 59% of older adults availed in-patient services, respectively, while 88%, 78% and 84% availed out-patient ones, respectively.
The authors attributed Kerala's high rates to "easy access and better availability of infrastructure". In Manipur and Tripura, it may be because people rely on nearby facilities during emergency in-patient situations, they said. Hilly states such as Nagaland, Sikkim and Himachal Pradesh could pose geographical challenges as 0%, 17% and about 5%of older adults in these areas made in-patient visits within 10 km, the study found. Further, in northeastern states, such as Mizoram and Nagaland, a higher percentage of older adults were found to travel more than 60 km to access in-patient and out-patient services, indicating a poor and limited access to nearby facilities.
Uttar Pradesh, Bihar, and Madhya Pradesh showed a moderate proximity of 11-60 km for older adults accessing out-patient care, but a higher share of in-patient visits at distances beyond 30 km.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Hindu
4 hours ago
- The Hindu
From Obesity to Ozempic: Is This the Right Way to Lose Weight?
The food landscape has undergone a dramatic shift over the years, and the numbers tell a sobering story. A study in The Lancet found that childhood and adolescent obesity rates worldwide have risen nearly fourfold from 1990 to 2022, while adult obesity rates have more than doubled. At the same time, dramatic celebrity weight loss has been linked to Ozempic, an injectable drug containing semaglutide, originally developed to treat type 2 diabetes but now widely used off-label as a weight-loss aid. In this weekender episode of In Focus, we ask: Why is it becoming harder to lose weight? What role do our gut and brain play in shaping our relationship with food? And should drugs like Ozempic step in where lifestyle changes and willpower fall short? Guest: Dr Jack Mosley, the author of Food Noise: How weight loss medications & smart nutrition can silence your cravings Host: Preeti Zechariah Edited by Jude Francis Weston and Sharmada Venkatasubramanian
India Today
2 days ago
- India Today
Prime Minister Modi calls for 10% less oil use to fight obesity crisis in India
Obesity rates have surged in recent years, with a Lancet study earlier this year warning about the alarming speed at which the condition is spreading worldwide. The study predicts that by 2050, more than one-third of India's population will be classified as the issue in his Independence Day speech, Prime Minister Narendra Modi urged Indians to take small but meaningful steps towards better health. Among his suggestions was a call to buy at least 10% less cooking oil and to use 10% less oil in daily I talk about fitness, I have a concern that I need to highlight. Obesity is becoming a huge public health problem for India. It is projected that at least one in three people will become obese. We have to get freedom from obesity. That's why I suggested that every family decide to buy 10% less oil, use 10% less oil, and participate in the fight against obesity,' said Prime Minister Modi in what became his longest Independence Day address to Independence Day in his address to the nation, Prime Minister Shri Narendra Modi ji highlighted that true freedom includes being free from lifestyle diseases. With obesity on the rise, small steps like using only 10% oil can make a big embrace healthier Ministry of Health (@MoHFW_INDIA) August 15, 2025 Prime Minister Modi's suggestion essentially promotes a gradual reduction in daily calorie intake. Oil, being highly calorie-dense, is an easy starting point. Just one tablespoon (about 15 ml) contains around 120 calories are not always obvious, but they add up quickly. Cutting oil use by 10% — even without changing the volume of food — can make a difference over time. For example, if someone typically uses three tablespoons of oil a day, reducing that by 10% means consuming about 36 fewer calories daily. While that number may seem small, such reductions, sustained over months or years, can lead to noticeable weight now ranks third in the world for the highest number of overweight and obese individuals, after the United States and approach does not compromise satiety, meaning people are less likely to feel deprived or overcompensate by eating more elsewhere. Reducing oil use also lowers the amount of excess dietary fat that can be easily stored as body fat, and encourages more mindful cooking habits, helping people become aware of hidden calories in other essence, its not a drastic diet change or a major taste sacrifice, just a subtle change that gradually chips away at excess calorie experts often say that such small, sustained adjustments, combined with better food choices and active lifestyles, could make a meaningful dent in India's growing obesity crisis, which is amplified by lifestyle shifts and the introduction of convenience ultra-processed foods.- EndsMust Watch
Mint
3 days ago
- Mint
Mint Explainer: The concerns around India's rabies vaccine supply
A six-year-old's death in Delhi recently due to a dog bite prompted a Supreme Court directive that has sparked widespread furore. On Monday, the apex court directed municipal authorities to pick up and house all stray dogs in Delhi and parts of the National Capital Region (NCR) in dedicated shelters within eight weeks. This led to widespread outrage among citizens and animal advocacy groups who are concerned that the order may set a precedent for other cities and towns. On Thursday, the top court reserved its order on a plea seeking an interim stay on the 11 August order. To be sure, India has one of the highest burdens of rabies deaths globally, with dog bites being the primary cause. An estimated 5,700 people die from dog-mediated rabies annually in India, according to a 2024 Lancet study. A national plan to eliminate rabies caused by dog bites by 2030 is still underway, but the country has made significant strides in reducing cases. Amid the ongoing controversy, Mint takes a look at India's rabies vaccine market and examines how access is shaping up. The plan In accordance with the WHO's 2015 call to eliminate dog-mediated rabies by 2030, the Indian government in 2021 announced the National Action Plan for Rabies Elimination (NAPRE), which aims to eliminate dog-mediated rabies from the country by 2030. Under NAPRE, the state has issued a set of guidelines for states and stakeholders to develop their own action plans, and aims to reduce rabies risk through sustained mass dog vaccinations, pre- and post-exposure prophylaxis, and public education. Continued availability of the anti-rabies vaccine (ARV) and rabies immunoglobulins (RIG) is key to eliminating human rabies by 2030, a 2019 research paper by the Association for Prevention and Control of Rabies in India (APCRI) noted. The rise and drop in cases According to a fisheries, animal husbandry and dairying ministry press release, dated 1 April 2025, dog bite cases and deaths across the country have increased from 2022 to 2024. In 2022, the country reported close to 2.2 million cases. In 2023, this increased to 3.05 million, in 2024 to 3.7 million. In January 2025, there were over 400,000 reported cases of dog bites. Human deaths from rabies grew from 21 in 2022 to 50 in 2023 and 54 in 2024, according to the release. In January 2025, there was one reported case of death. It is important to note that many cases of dog bites go unreported due to a lack of awareness, and as people often don't get vaccinated in time. A recent study backed by the Indian Council of Medical Research (ICMR) and published in The Lancet, noted that India has made significant strides in reducing rabies-related deaths. In the past two decades, India has witnessed a 75% decline in dog-mediated human rabies deaths, most likely due to the increased availability of ARV and RIG in the health facilities, the study, which surveyed 534 health facilities across 60 districts in 15 states, stated. Is there a shortage of vaccines? According to the Lancet study, a majority of public healthcare facilities in India maintained stocks of anti-rabies vaccines. They were found in 80% of the facilities and 90% of secondary and tertiary care centres. Meanwhile, 95% of district hospitals and 92% of medical colleges had stocks. However, what is lacking is the availability of rabies immunoglobulins. Four out of five facilities surveyed lacked immunoglobulin stocks. The largest shortage was at the primary care level, where over 94% facilities lacked supplies. Immunoglobulins are administered around the wound to neutralise the virus, especially in cases of severe bites. This is followed by the administration of a series of 4-5 rabies vaccine shots over a period of 28 days. The course of treatment is decided based on the severity of the wound and the status of the animal. Immunoglobulins are critical in arresting the spread of the virus and preventing death. Reports of shortages in states and cities persist. Earlier this month, Times of India reported a shortage of vaccines in BMC-run hospitals in Mumbai. Chennai reported a shortage in June 2025. There is no shortage in the supply of vaccines, a National Centre of Disease Control (NCDC) official told Mint on the condition of anonymity. However, given that it is a decentralised procurement system, where states are allocated funds and procure vaccines on their own, there could be issues. In instances of disproportionate increase in animal bite cases, there may be issues with appropriate prediction and stocking at the state level, the official said. The central government released ₹68.86 crore in funds for procurement of vaccines to states in FY21. In FY22, ₹62.33 crore, ₹98.75 crore in FY23 and ₹99.77 crore in FY24, according to the Ministry of Health and Welfare's written Rajya Sabha reply in December 2023. Who makes these vaccines? India is one of the largest manufacturers of rabies vaccines globally, and most of the country's needs are met by indigenous products. Geographically, supply is 85% concentrated in China and India, a WHO global market study on human rabies vaccines from 2020 pointed out. There are currently ten manufacturers of anti-rabies vaccines in the country. The top selling brands are Rabivax by Serum Institute of India (SII), Abhayrab by Indian Immunologicals, and Chirorab by Bharat Biotech, according to data from pharma intelligence platform Pharmarack. Other players include Sun Pharma, Mankind Pharma, and Zydus Cadila. However, there are only four immunoglobulins manufactured in India - two by Mankind and two by Indian Immunologicals and Serum Institute which have a negligible market share. There are two types of immunoglobulin available–equine rabies immunoglobulins (RIGs), which are indigenously produced, and human RIGs, which are imported. Human RIGs are considered to be safer and more effective, especially in children, according to studies. The overall market for rabies vaccines in India was ₹266 crore in July 2025 on a moving annual total basis, according to Pharmarack, a B2B e-commerce platform. Of this, ₹240 crore was for ARVs and ₹25 crore for immunoglobulins. A total of 7,593 units of both ARV and RIG were sold as of July 2025. The number of units sold monthly has remained steady between 2023 and the current date, with a slight uptick in recent months, the data showed. Cost remains an issue in accessing rabies vaccines as well. While they are provided free of charge in public facilities, the cost of one vial of ARV is typically between ₹350 and ₹400 in private hospitals. According to the WHO, the cost of post-exposure prophylaxis (PEP), the regimen of human RIG and ARV administered after the bite, is the highest in Asia.
